## Core Concept
The scenario presents a 37-year-old primigravida (first-time pregnant woman) who is Rh negative, at 16 weeks of gestation, and has a normal triple test report but is concerned about her age-related risk for chromosomal abnormalities. Amniocentesis is a diagnostic test that can detect chromosomal abnormalities, such as Down syndrome, and is often offered to women over 35 years due to their increased risk. However, Rh-negative women require special consideration to prevent Rh alloimmunization.

## Why the Correct Answer is Right
Administering Rh immune globulin (RhIg) is crucial for Rh-negative pregnant women to prevent isoimmunization, which can occur if fetal Rh-positive blood enters the maternal circulation. This is particularly relevant in procedures that may cause fetomaternal bleeding, such as amniocentesis. The administration of RhIg can help prevent the formation of anti-Rh antibodies, which could attack a future Rh-positive fetus.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is blank and does not provide any information.
- **Option B:** This option is also blank and does not provide any relevant information for consideration.
- **Option C:** Similarly, this option does not offer any details and cannot be evaluated.
- **Option D:** Without specific details on what each option entails, we focus on the rationale for RhIg administration.

## Clinical Pearl / High-Yield Fact
A key point to remember is that all Rh-negative pregnant women should receive Rh immune globulin (RhIg) at 28 weeks of gestation and within 72 hours of any potentially sensitizing event (like amniocentesis or a miscarriage). This significantly reduces the risk of Rh alloimmunization.

## Correct Answer Line
**Correct Answer: .**